Parc Sanitari Sant Joan de Deu, Universitat de Barcelona, CIBERSAM, C/ Doctor Antoni Pujadas 42, 08830 Sant Boi de Llobregat, Barcelona, Spain.
Lundbeck SAS, 37-45 Quai du Président Roosevelt, 92445, Issy-les-Moulineaux, France.
BMC Psychiatry. 2018 Mar 27;18(1):80. doi: 10.1186/s12888-018-1657-3.
Patients who require a switch in their antidepressant therapy may have different clinical profiles and treatment needs compared with patients initiating or maintaining a first-line antidepressant therapy.
The Prospective Epidemiological Research on Functioning Outcomes Related to Major depressive disorder (MDD) (PERFORM) study was a 2-year observational cohort study in outpatients with MDD in five European countries. Enrolled patients were either initiating or undergoing the first switch to an antidepressant monotherapy. Baseline data on patients' clinical status, functioning, productivity, quality of life and medical-resource use were compared in a cross-sectional baseline analysis.
A total of 1402 patients were enrolled, of whom 1159 (82.7%) provided analysable baseline data. The majority (78.7%) of the analysable population were initiating antidepressant treatment and most (83.6%) were enrolled and followed up by general practitioners. Compared with patients initiating antidepressants, those switching antidepressants (21.3%) tended to have more severe depressive symptoms, greater anxiety, worse health-related quality of life, greater functional impairment, greater medical-resource use and had a different medical history. Limitations included an over-representation of switches due to lack of efficacy among patients who were switching treatment, as patients were selected based on presence of depressive symptoms.
Patients with MDD who are switching treatment for the first time have a different profile and different depression-associated health needs compared with those initiating treatment. Therapeutic management should therefore be adapted for patients who switch.
ClinicalTrials.gov NCT01427439 ; Retrospectively registered 26 August 2011.
与起始或维持一线抗抑郁治疗的患者相比,需要转换抗抑郁治疗的患者可能具有不同的临床特征和治疗需求。
前瞻性与功能结局相关的重性抑郁障碍(MDD)流行病学研究(PERFORM)是一项在五个欧洲国家的门诊 MDD 患者中进行的为期 2 年的观察性队列研究。纳入的患者要么起始要么正在进行第一次转换为抗抑郁单药治疗。在横断面基线分析中比较了患者临床状态、功能、生产力、生活质量和医疗资源使用的基线数据。
共纳入 1402 例患者,其中 1159 例(82.7%)提供了可分析的基线数据。分析人群中的大多数(78.7%)正在起始抗抑郁治疗,大多数(83.6%)由全科医生招募和随访。与起始抗抑郁药物治疗的患者相比,转换抗抑郁药物治疗的患者(21.3%)往往具有更严重的抑郁症状、更高的焦虑、更差的健康相关生活质量、更严重的功能障碍、更多的医疗资源使用和不同的病史。局限性包括由于治疗转换的患者缺乏疗效而导致转换治疗的患者比例过高,因为患者是根据抑郁症状存在而被选择的。
首次转换治疗的 MDD 患者与起始治疗的患者相比,具有不同的特征和不同的与抑郁相关的健康需求。因此,应根据患者的具体情况调整治疗管理。
ClinicalTrials.gov NCT01427439;于 2011 年 8 月 26 日回顾性注册。